Remove 2020 Remove Documentation Remove Medication Dispensing
article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

(Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

(Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

(Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. Which is why, according to some online reports, nearly 80% of new drug introductions are now specialty medications.

article thumbnail

How Recent 340B Changes Impact Specialty Pharmacies In 2025

Proxsys Rx

NOTE: Despite all the ploys manufacturers have undertaken over the years, every one of the 21 health systems whose 340B programs are managed by ProxsysRx have enjoyed increased 340B savings and revenue since the introduction of the first restrictions in 2020. Subsequent 340B legal cases: Novartis Pharmaceuticals Corporation v.